Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23293911 | 0.98 | ALDH1A1 (0.47) | ALDH1A1KDM4ETSHRCYP2C19LMNA | |
| SCHEMBL3273017 | 0.91 | OGFRL1 (0.46) | ALDH1A1KDM4ETSHRCYP2C19LMNA | |
| SCHEMBL30226610 | 0.91 | ALDH1A1 (0.46) | ALDH1A1KDM4ETSHRCYP2C19LMNA | |
| SCHEMBL321188 | 0.89 | OGFRL1 (0.48) | ALDH1A1KDM4EHSD17B10OGFRL1 | |
| Hydrochloric Acid SCHEMBL4151575 | 0.89 | ALDH1A1 (0.49) | ALDH1A1KDM4ETSHRCYP2C19LMNA | |
| SCHEMBL3273617 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNADUSP3MEN1KMT2A | |
| SCHEMBL3273616 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNADUSP3MEN1KMT2A | |
| SCHEMBL13291085 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNADUSP3MEN1KMT2A | |
| SCHEMBL31334651 | 0.85 | CHRM1 (0.45) | ALDH1A1LMNACHRM1L3MBTL1MAPT | |
| SCHEMBL4155085 | 0.85 | TSHR (0.61) | ALDH1A1KDM4ETSHRCYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-05-26 | — | — | US | disclosed |
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260078085-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| US-12503432-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-12-23 | — | — | US | disclosed |
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | SIRONAX BEIJING CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| EP-4200298-B1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119866332-A | Iron death inhibitor-phenoxazine acetamides | 维泰瑞隆（北京）生物科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-1303513-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL] CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6534531-B2 | Thiazole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-18 | — | — | US | disclosed |
| EP-1282419-A2 | METHODS FOR PREVENTING AND TREATING ALOPECIA INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6515004-B1 | Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| EP-1240166-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-23 | — | — | US | disclosed |
| WO-2002010162-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL] CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001044242-A9 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001080813-A2 | METHODS FOR PREVENTING AND TREATING ALOPECIA INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001044242-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | AIFM2, GPX4, FECH | ALDH1A1 1064/4885KDM4E 3427/4885TSHR 3713/4885 |
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR3 | ALDH1A1 3124/4885KDM4E 1311/4885TSHR 789/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | ALDH1A1 4385/4885KDM4E 1212/4885TSHR 3696/4885 |
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | NSUN2, NSUN3, RNMT | ALDH1A1 1643/4885KDM4E 1647/4885TSHR 3269/4885 |
| US-20260078085-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | NSUN2, NSUN3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 1732/4885KDM4E 3442/4885TSHR 2984/4885 |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | NR5A1, CYP17A1, CYP21A2 | ALDH1A1 210/4885KDM4E 2440/4885TSHR 3731/4885 |
| US-12503432-B2 | Ionizable lipids for nucleic acid delivery | RNASEH1, NSUN3, SLC67A1 | ALDH1A1 2638/4885KDM4E 3209/4885TSHR 2325/4885 |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | ALDH1A1 1232/4885KDM4E 1554/4885TSHR 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.